Custom service

DNA Immunization Antibody Production

The animal expresses the antigen; you skip the protein.

Timeline: 12–18 weeks — including boostsDelivery: Gene gun, EP — intradermal, intramuscularAdvantage: Native folding — in vivo PTM and topology

Protein expression is the bottleneck in most antibody projects, and for some targets it never resolves: a toxic protein kills the host, a membrane protein aggregates without lipid, a heavily glycosylated antigen loses its epitopes in E. coli. DNA immunisation removes that step by delivering a plasmid that the animal's own cells transcribe and translate, presenting the antigen with native folding, disulfide bonding and post-translational modification.

Delivery matters as much as the construct. Intradermal gene gun bombardment deposits DNA-coated gold particles directly into epidermal cells, where the density of antigen-presenting cells is high; intramuscular injection followed by electroporation achieves higher transfection efficiency but deeper tissue. Codon optimisation, a mammalian signal peptide and, for membrane proteins, a truncated or full-length topology are engineered into the construct before the first injection.

The immune response to DNA is Th1-skewed and biased toward conformational epitopes, which suits receptor and membrane targets and is less effective for small linear epitopes. A common design is DNA prime followed by a protein or VLP boost, which combines the conformational breadth of genetic delivery with the stronger germinal centre reaction a protein antigen produces.

Service Highlights

Where it fits

DNA immunisation is the method of choice for membrane proteins, toxic antigens and proteins that are difficult to purify in a native conformation. It is also useful when the antigen must be presented exactly as it appears on a cell surface, since the animal's cells perform the folding and glycosylation.

It is a weaker route for small peptides, for antigens requiring strong adjuvanticity, and for projects where titre must build quickly — DNA responses are slower and often lower than protein responses, which is why the prime–boost design is used so often.

Documentation and QC

Constructs are fully sequenced and expression-verified before use. Serum titres are reported throughout, and the fusion report includes screening data on target-expressing and control cells. The plasmid is supplied at the end of the project, with a map and sequence file.

Frequently asked questions

Is DNA immunisation less effective than protein?

For titre, usually yes. For conformational epitopes on membrane proteins, often better. The choice depends on what the antibody has to recognise rather than on a general ranking.

What if the construct does not express?

We test expression in HEK293 before immunisation. If it fails, the construct is redesigned — signal peptide, codon usage, or a truncated soluble form — at no additional animal cost.

Can this be combined with a protein boost?

Yes, and for most targets it should be. DNA prime followed by a protein or VLP boost is the schedule we recommend when a recombinant antigen is available.

Send the target sequence and tell us whether a recombinant protein exists. If it does, we will likely propose a prime–boost schedule; if it does not, DNA alone is still a workable route.

Service Highlights

  • Construct design in house. Codon optimisation, signal peptide selection, transmembrane or secreted format, and epitope tagging decided before synthesis.
  • Two delivery routes. Gene gun for epidermal transfection, intramuscular electroporation for higher expression; both validated by in vivo imaging where relevant.
  • In vivo expression check. Transfected cell lysates and injected tissue are checked for expression before immunisation is scheduled, so a silent construct is caught early.
  • DNA prime, protein boost. The most reliable schedule for conformational targets, combining breadth with titre.
  • No protein required. Useful for targets that cannot be expressed in vitro, and for antigens that are hazardous to produce at scale.
  • Sequence preserved. The plasmid is archived and supplied, so the immunogen can be reproduced exactly in a later campaign.

How the work runs

  1. Antigen design

    Sequence, topology and expression host are reviewed. Signal peptide, transmembrane domains and codon usage are optimised, and the construct is synthesised and sequence-verified.

  2. Expression validation

    HEK293 cells are transfected and analysed by Western blot or flow to confirm the construct expresses the expected product before animals are used.

  3. Immunisation

    Gene gun or electroporation, four to six doses at two- to three-week intervals, with serum titre monitored from week six.

  4. Optional protein boost

    Where a recombinant protein exists, a final protein boost two weeks before fusion increases the plasmablast population.

  5. Fusion and screening

    Standard fusion; screening on cells expressing the target rather than on purified protein, to preserve the conformational advantage.

  6. Cloning and characterisation

    Subcloning, isotyping and application-specific testing, with the plasmid supplied for future boosts.

Specifications & timeline

Timeline
12–18 weeks — including boosts
Delivery
Gene gun, EP — intradermal, intramuscular
Advantage
Native folding — in vivo PTM and topology
Vector
pcDNA3.1-based mammalian expression vector, codon-optimised, with optional tag
Delivery
Helios gene gun or intramuscular electroporation
Timeline
12–18 weeks including construct synthesis and expression validation
Doses
4–6 immunisations at 2–3 week intervals, 20–50 µg DNA per dose
Screening
Flow cytometry on transfected cells, Western blot, ELISA where protein is available
Deliverables
2–5 hybridomas, plasmid stock, expression validation data, isotype report

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.